Distribution Curve, page-32

With respect Teddy, there are many questions there it would be unreasonable to ask the head oncologist. I do not intend grilling her over investor presentation attendees etc. I do intend to find out if the trial is complete, if not how many are still enrolled and how many need to progress. And I also hope to get a feel of what she makes of the length of the trial. I would like to get some idea of when top line data might be released as well. Tracy is not really the one to barrage with questions from left field, I'll be grateful if she just returns my call and gives me some clues on the above. I tried to sound as harmless as possible on the message I left.